High prevalence of low high-density lipoprotein cholesterol concentrations and other dyslipidemic phenotypes in an Iranian population

Metabolic Syndrome and Related Disorders

Volumn 6, Issue 3, 2008, Pages 187-195

  Sharifi, F ^a,c   Mousavinasab, S N ^a   Soruri, R ^b   Saeini, M ^a   Dinmohammadi, M ^c  

^a ZANJAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b ZANJAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c ZANJAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

[No Author keywords available]

Indexed keywords

HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID;

ADULT; AGED; ARTICLE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DYSLIPIDEMIA; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTRIGLYCERIDEMIA; HYPOALPHALIPOPROTEINEMIA; IRAN; LIFESTYLE MODIFICATION; MAJOR CLINICAL STUDY; MALE; MIXED DYSLIPIDEMIA; PHENOTYPE; POPULATION; PREVALENCE; PRIORITY JOURNAL; RISK FACTOR; SEVERE DYSLIPIDEMIA; URBAN AREA;

ADULT; AGED; CHOLESTEROL, HDL; CORONARY ARTERY DISEASE; DYSLIPIDEMIAS; FEMALE; HUMANS; HYPERCHOLESTEROLEMIA; HYPERTRIGLYCERIDEMIA; HYPOALPHALIPOPROTEINEMIAS; IRAN; LIFE STYLE; MALE; MIDDLE AGED; PREVALENCE; RISK FACTORS;

EID: 51349086698     PISSN: 15404196     EISSN: None     Source Type: Journal    
DOI: 10.1089/met.2008.0007     Document Type: Article

References (35)

1. Mirmiran P, Azizi F. Obesity. In: Azizi F, Hatami H, Jangorbani M, eds. Epidemiology and control of prevalent disease in Iran, 2nd ed. Tehran: Eshtiagh Press, 2001:56-69 [in Persian].
2. Sharifi F, Azizi F. The prevalence of hyperlipidemia, overweight and blood pressure in diabetic and IGT patients and their comparison to healthy subjects in rural areas of Zanjan. Res Medicine 1997;21:41-50 [in Persian].
3. Stamler J , Wentworth D , Neaton J. Is the relationship between serum cholesterol and risk of death from coronary heart disease continuous and graded? Findings on the 356,222 primary screens of the Multiple Risk Factor Intervention Trial (MRFIT). J Am Med Assn 1986;25:2823-2829.
4. Rose G, Shipley M. Plasma cholesterol and death from coronary disease: 10 year results of the Whitehall study. B. Med J 1986;29:306.
5. Gotto A. M. Risk factor modification: rationale for management of dyslipidemia. Am J Med 1998;104:6S-8S.
6. Castelli W. P. Epidemiology of coronary heart disease. The Framingham Study. Am J Med 1984;7:4.
7. Grundy S. M, Pasternak R, Greenland P, Smith S, Fuster V. Assessment of cardiovascular risk by use of multiple risk factor assessment equations. Circulation 1999;100:1481-1492.
8. Fager G, Wiklung O. Cholesterol reduction and clinical benefit. Are there limits to our expectations? Arterioscler Thromb Vasc Biol 1997;17:3527-3533.
9. Miettinen T, Pyöralä K , Olsson A, Musliner T, Cook T, Faergeman O, Berg K, Pedersen T, Kjelshus J. Cholesterol lowering therapy in women and elderly patients with myocardial infarction or angina pectoris. Circulation 1997;96:4211-4218.
10. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, Mac-Farlane PW, McKillop JH, Packard CJ. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995;333:1301.
11. Uçar B, Kiliç Z, Dinleyici EC, Colak O, Güneş E. Prevalence of dyslipidemia in the Iraqi adult population. Saudi Med J. 2007;28:1868-1874.
12. Mula-Abed WS, Chilmeran SK. Lipid and lipoprotein profiles and prevalence of dyslipidemia in Mexican adolescents. Metabolism. 2007; 56:1666-1672.
13. Azizi F, Esmaillzadeh A, Mirmira P. Obesity and cardiovascular disease risk factors in Tehran adults: a population-based study. Eastern Medit Health J 2004;10:887.
14. Chehrei A, Sadrnia S, Keshteli AH, Daneshmand MA, Rezaei J. Correlation of dyslipidemia with waist to height ratio, waist circumference, and body mass index in Iranian adults. Prev Med. 2004;39:760-766.
15. Kelishadi R, Pour MH, Zadegan NS, Kahbazi M, Sadry G, Amani A, Ansari R, Alikhassy H, Bashardoust N. Dietary fat intake and lipid profiles of Iranian adolescents: Isfahan Healthy Heart Program - Heart Health Promotion from Childhood. Asia Pac J Clin Nutr 2007;16:248-253.
16. Assmann G, Schulte H. Results and conclusions of the Prospective Cardiovascular Münster (PROCAM) Study. In Lipid Metabolism Disorders and Coronary Heart Disease. G. Assmann, ed. MMV Medizin Verlag, 1993;21;-67.
17. Austin M, Hokanson J E, Edwards K. Hypertriglyceridemia as a cardiovascular risk factor. Am J Cardiol 1998;81:7B1993 12B.
18. Demacker PN, Hessels M, Toenhake-Dijkstra H, Baadenhuijsen H. Precipitation methods for high -density lipoprotein cholesterol measurement compared , and final evaluation under routine operating conditions of a method with low sample-to- reagent ratio. Clin Chem 1997;43:663-668.
19. Warnick GR, Nguyen T, Albers AA. Comparison of improved precipitation methods for quantification of high-density lipoprotein cholesterol. Clin Chem 1985;31:217-222.
20. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972;18:499-502.
21. Aguilar-Salinas CA , Olaiz G, Valles V, Ríos Torres JM, Gómez Pérez FJ, Rull JA, Rojas R, Franco A, Sepulveda J. High prevalence of low HDL cholesterol concentrations and mixed hyperlipidemia in a Mexican nationwide survey. Lipid Res 2001;42:1298-1307.
22. National Center for Health Statistics. Plan and operation of the Third National Health and Nutrition Examination Survey 1988-1994. Vital Health Stat 1994;1:32.
23. Bhopal R, Unwin N, White M, et al. Heterogeneity of coronary heart disease risk factors in Indian, Pakistani, Bangladeshi, and European origin populations: cross sectional study. BMJ 1999;319:215-220.
24. Mahley RW, Pépin J, Palaolu KE , Malloy MJ , Kane JP, Bersot TP. Low levels of high density lipoproteins in Turks, a population with elevated hepatic lipase: high density lipoprotein characterization and gender-specific effects of apolipoprotein E genotype. Lipid Res 2000;41:1290-1301.
25. Stern MP, Gonzalez Villalpando C , Mitchell B , Villalpando E, Haffner S, Hazuda H. Genetic and environmental determinants of type II diabetes in Mexico City and San Antonio. Diabetes 1992;41:484-492.
26. Parks E J, Hellerstein M K. Carbohydrate induced hypertriacylglycerolemia: historical perspective and review of biological mechanisms. Am J Clin Nutr 2000;71:412-433.
27. Asztalos B , Lefevre M, Wong L, Foster T, Tulley R, Windhauser M, Zhang W, Roheim P. Differential response to low fat diet between low and normal HDL cholesterol subjects. J Lipid Res 2000;41:321-328.
28. WHO Global Infobase. Iran: Most recent national survey(s) for chronic, non-communicable diseases risk factors. Accessed at http://www.who.int/infobase/ .
29. Azizi FL. Dietary factors and body mass index in a group of Iranian adolescents: Tehran lipid and glucose study-2. Int J Vitamin Nutr Res 2001;71:123-127.
30. Azizi F. Serum lipid levels in an Iranian adults population: Tehran lipid and glucose study. Eur J Epidemiol 2003;18:311-319.
31. Prevalence of low high-density lipoprotein cholesterol in patients with documented coronary heart disease or risk equivalent and controlled low-density lipoprotein cholesterol. Am J Cardiol 2007;100:1499-1501.
32. Arca M, Montali A, Valiante, S, Campagna F, Pigna, G, Paoletti V, Antonini R, Barillá F, Tanzilli G, Vestri A, Gaudio C. Usefulness of atherogenic dyslipidemia for predicting cardiovascular risk in patients with angiographically defined coronary artery disease. Am J Cardiol 2007 Nov 15;100(10):1511-1516. Epub 2007 Oct 4.
33. Gaw A. Evidence based approach for the management of mixed hyperlipidemia. Atherosclerosis 1998;137(Suppl):S97-S100.
34. Alsheikh-Ali AA, Lin JL, Abourjaily P, Ahearn D, Kuvin JT, Karas RH. Serum lipid profiles including non-high density lipoprotein cholesterol levels in Turkish school-children. Anadolu Kardiyol Derg 2007;7:415-420.
35. Goh VH, Tong TY, Mok HP, Said B. Differential impact of aging and gender on lipid and lipoprotein profiles in a cohort of healthy Chinese Singaporeans. Asian J Androl 2007;9:787-794.